Syndax Pharmaceuticals Inc Stock News

LOS ANGELES--(BUSINESS WIRE)---- $SNDX--SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law.

NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib), the Company's first-in-class menin inhibitor, has been selected by TIME as one of the “Best Inventions of 2026” in the Medical and Healthcare category. TIME's annual list of the Best Inv...

– Trial did not meet the primary endpoint of annualized rate of FVC decline – – Axatilimab was well tolerated with a safety profile comparable to placebo; no new safety signals were observed – – Axatilimab continues to advance in multiple trials in cGVHD with results expected later this year and early 2028 – NEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX) today...

NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2026, the Company granted inducement awards to purchase up to 213,300 shares of common stock to nine new employees under the Company's 2023 Inducement Plan. The stock options will vest over four ...

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest ove...

Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as potential reward. Nochomovitz has a $7 target on Biomea Fusion, implying about 410% upside from the price used in Citi's call, while his $57 Syndax Pharmaceuticals target points to roughly 190%.

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2026, the Company granted inducement awards to purchase up to 59,250 shares of common stock to five new employees under the Company's 2023 Inducement Plan. The stock options will vest over four ye...